TY - JOUR
T1 - Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain
AU - Roel, Elena
AU - Pistillo, Andrea
AU - Recalde, Martina
AU - Sena, Anthony G.
AU - Fernández-Bertolín, Sergio
AU - Aragón, Maria
AU - Puente, Diana
AU - Ahmed, Waheed Ul Rahman
AU - Alghoul, Heba
AU - Alser, Osaid
AU - Alshammari, Thamir M.
AU - Areia, Carlos
AU - Blacketer, Clair
AU - Carter, William
AU - Casajust, Paula
AU - Culhane, Aedin C.
AU - Dawoud, Dalia
AU - DeFalco, Frank
AU - DuVall, Scott L.
AU - Falconer, Thomas
AU - Golozar, Asieh
AU - Gong, Mengchun
AU - Hester, Laura
AU - Hripcsak, George
AU - Tan, Eng Hooi
AU - Jeon, Hokyun
AU - Jonnagaddala, Jitendra
AU - Lai, Lana Y.H.
AU - Lynch, Kristine E.
AU - Matheny, Michael E.
AU - Morales, Daniel R.
AU - Natarajan, Karthik
AU - Nyberg, Fredrik
AU - Ostropolets, Anna
AU - Posada, Jose D.
AU - Prats-Uribe, Albert
AU - Reich, Christian G.
AU - Rivera, Donna R.
AU - Schilling, Lisa M.
AU - Soerjomataram, Isabelle
AU - Shah, Karishma
AU - Shah, Nigam H.
AU - Shen, Yang
AU - Spotniz, Matthew
AU - Subbian, Vignesh
AU - Suchard, Marc A.
AU - Trama, Annalisa
AU - Zhang, Lin
AU - Zhang, Ying
AU - Ryan, Patrick B.
AU - Prieto-Alhambra, Daniel
AU - Kostka, Kristin
AU - Duarte-Salles, Talita
N1 - Publisher Copyright:
© 2021 The Authors; Published by the American Association for Cancer Research
PY - 2021/10
Y1 - 2021/10
N2 - Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin’s lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n ¼ 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
AB - Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin’s lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n ¼ 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
UR - http://www.scopus.com/inward/record.url?scp=85116992369&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0266
DO - 10.1158/1055-9965.EPI-21-0266
M3 - Article
C2 - 34272262
AN - SCOPUS:85116992369
SN - 1055-9965
VL - 30
SP - 1884
EP - 1894
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 10
ER -